Jacobs Levy Equity Management Inc. Takes $450,000 Position in 10x Genomics, Inc. (NASDAQ:TXG)

Jacobs Levy Equity Management Inc. purchased a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 31,367 shares of the company's stock, valued at approximately $450,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Signaturefd LLC increased its holdings in 10x Genomics by 424.6% during the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after acquiring an additional 1,452 shares in the last quarter. Blue Trust Inc. grew its position in shares of 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock valued at $44,000 after purchasing an additional 1,299 shares during the last quarter. Sound Income Strategies LLC increased its stake in shares of 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after purchasing an additional 1,330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of 10x Genomics during the 4th quarter worth approximately $52,000. Finally, SRS Capital Advisors Inc. lifted its stake in 10x Genomics by 817.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock valued at $70,000 after buying an additional 4,324 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Morgan Stanley dropped their price target on 10x Genomics from $26.00 to $18.00 and set an "overweight" rating for the company in a research report on Monday. UBS Group dropped their price objective on 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Stephens reissued an "overweight" rating and issued a $14.00 target price on shares of 10x Genomics in a research note on Thursday, May 15th. Citigroup decreased their price target on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Finally, Barclays cut their price objective on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, 10x Genomics presently has an average rating of "Hold" and an average price target of $15.81.

10x Genomics Trading Down 3.9%

Shares of TXG traded down $0.34 during mid-day trading on Friday, reaching $8.21. The company had a trading volume of 371,894 shares, compared to its average volume of 3,200,929. 10x Genomics, Inc. has a fifty-two week low of $6.78 and a fifty-two week high of $24.76. The firm has a fifty day simple moving average of $8.63 and a 200-day simple moving average of $12.15. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -5.40 and a beta of 1.94.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.09. The firm had revenue of $154.88 million during the quarter, compared to the consensus estimate of $131.91 million. 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. The firm's quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.50) earnings per share. As a group, equities analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Insider Transactions at 10x Genomics

In other news, insider Benjamin J. Hindson sold 4,573 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the sale, the insider now owns 335,324 shares of the company's stock, valued at $3,712,036.68. This represents a 1.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Serge Saxonov sold 5,092 shares of the company's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the transaction, the chief executive officer now owns 879,482 shares of the company's stock, valued at approximately $9,735,865.74. This represents a 0.58% decrease in their position. The disclosure for this sale can be found here. Company insiders own 9.39% of the company's stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.